BioCentury
ARTICLE | Finance

Analyze this

Why Chi-Med listed on NASDAQ

March 28, 2016 7:00 AM UTC

With a host of clinical data events coming in 12-18 months, Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) sought a U.S. listing to gain access to specialists and analysts who can help the Hong Kong company's predominantly generalist investor base better understand its cancer pipeline.

Last week, Chi-Med raised $101.3 million through the sale of 7.5 million ADSs at $13.50 in a NASDAQ listing. BofA Merrill Lynch, Deutsche Bank Securities, Stifel, Canaccord Genuity, Panmure Gordon and CITIC were underwriters...